Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT05360537
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT05360537
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Italy
- Registry status
- Completed
Technical summary
Registry record NCT05360537. Randomized; double masking; primary purpose treatment. Start 2021-04-01 (actual); primary completion 2021-12-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin Degludec / Liraglutide Injectable Product
- Intervention (Drug)
- Insulin Glargine
- Lead sponsor
- University of Palermo
Record details
- Record id
cardio:ct-nct05360537- Content hash
ffac486444c2f9f60f9e52613461fc10aaf93b5d344d363abf073da29a74d3df